PsA Efficacy Data

 
ACR=American College of Rheumatology; BID=twice daily; csDMARD=conventional synthetic disease-modifying antirheumatic drug; DSS=Dactylitis Severity Score; IR=inadequate responder; JAK=Janus kinase; JAKi=Janus kinase inhibitor; LEI=Leeds Enthesitis Index; MOA=mechanism of action; mTSS=modified Total Sharp Score; NS=not significant; PASI=psoriasis area and severity index; PsA=psoriatic arthritis; q 2 wk=every 2 weeks; RA=rheumatoid arthritis; SC=subcutaneously; TNFi=tumor necrosis factor inhibitor.
 
References: 1. XELJANZ/XELJANZ XR [prescribing information]. New York, NY: Pfizer Inc.; December 2019. 2. Data on file. Pfizer Inc., New York, NY. 3. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537-1550. 4. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525-1536. 5. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis [supplementary appendix]. N Engl J Med. 2017;377(16):1537-1550. https://www.nejm.org/doi/suppl/10.1056/NEJMoa1615975/suppl_file/nejmoa1615975_appendix.pdf. Accessed March 5, 2019.